Researchers at the University of Colorado Cancer Centre have published their work on NLRP3 - an intracellular complex found to participate in melanoma-mediated inflammation leading to tumour growth and progression. The researchers found that by inhibiting this complex, they can reduce inflammation and tumour growth. The studies have so far used an oral NLRP3 inhibitor (Dapansutrile) which has shown to be effective in treating gout and heart disease. It is currently being tested in COVID-19. | https://medicalxpress.com/news/2021-04-drug-tumors.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
"Great ideas, research and innovation can come from anyone – so often the best ideas do not have a voice. IdeaSpies provides a platform for people to share ideas that create a better world"
Jonathan Chrimes
IdeaSpies